SCCA lymphoma specialists offer unique options
As survival rates for lymphoma are improving, the first therapy is typically the most effective and important. But patients may need more than one therapy. SCCA has one of largest and most comprehensive multidisciplinary lymphoma teams in the nation, and the largest team in the Northwest. Our team can offer both longitudinal direct or collaborative care along with the most innovative clinical trial offerings for patients with untreated or relapsed lymphoma. We can also provide guidance and continuous input through related therapies such as transplant and CAR T.
Lymphoma: incorporating CAR T therapies earlier than ever before
SCCA is the only facility in the Northwest — and one of the first in the U.S. — to offer two FDA-approved CAR T-cell therapies, Yescarta and Kymriah, for patients with relapsed or refractory aggressive large B-cell lymphoma. And we have dozens of active and upcoming clinical trials testing new approaches and therapies.
The current standard of care for many lymphomas places CAR T-cell therapy as a late or final option for treatment, usually following one failed course of chemotherapy and a bone marrow transplant. Clinical trials are offering CAR T-cell therapy earlier to see if it can improve outcomes.
“Patients who receive CAR T-cells with less disease burden appear to have less toxicity and also have better outcomes, with better survival and a better long-term remission rate,” says David Maloney, MD, PhD, who serves as Medical Director of Cellular Immunotherapy at SCCA. “If a patient is failing standard therapy, it’s important to consider if there are any clinical trials of these therapies, as early as possible.”
Lymphoma: transplants remain a key option for many
SCCA and its alliance partner, Fred Hutchinson Cancer Research Center, pioneered many groundbreaking lymphoma treatments, including stem cell and bone marrow transplants (BMT). The newer immunotherapies may decrease some types of transplant, but also may increase the ability for some patients with leukemia to receive transplants.
“Transplants revolutionized care,” says Marco Mielcarek, MD, PhD, who serves as Medical Director of SCCA’s Adult Blood and Marrow Transplant Program. “It’s exciting to have alternatives for a growing number of patients, and my team works closely with physicians across SCCA to explore those alternatives and make sure each patient gets matched with the therapy or clinical trial that’s right for them.”
Clinical trials that challenge the status quo
SCCA has numerous trials that challenge the status quo including multiple non-chemo oral treatment options for patients with newly diagnosed or recurrent lymphoma. Some trials incorporate immunotherapy as part of the first treatment for lymphoma and others include treatments that “link” tumor killing T-cells to lymphoma cells by a simple infusion or include novel immunostimulatory agents designed to further leverage the immune system to fight the cancer. SCCA promptly screens patients for appropriate trials and presents unique options, alongside the standard treatments.
One Phase 2 study gives patients Yescarta as soon as their cancer shows signs of progressing during chemotherapy.
“If patients with high risk lymphoma don’t respond quickly to their initial therapy, we can quickly offer a commercially-approved CAR even in their first line of therapy,” Dr. Maloney says.
We’re also offering a Phase 1/2 study of a third-generation therapy — the only one targeting the CD20 antigen, rather than CD19 — to see whether it’s even less toxic than existing CARs.
A third, Phase 3 study (NCT03575351) poses the most direct comparison between the current standard of care and early delivery of immunotherapy. All patients in this study have relapsed or refractory lymphoma following an initial course of chemotherapy. One group will move on to salvage chemotherapy and, if possible, BMT. The other group will be treated with JCAR017 — a new CAR T-cell based therapy, based on research at Fred Hutch, that provides an equal amount of modified CAR CD4 and CD8 and modified T-cells. The two patient groups will be compared across 14 metrics, with event-free survival as the primary outcome.
So far, JCAR017 (lisocabtagene marileucel) has proven to be effective with less severe toxicity.
“Because of our CAR T-cell center’s experience, we have been able to treat most of our patients on an outpatient basis, and 30 to 40 percent of patients do not require hospitalization during their course of treatment,” Dr. Maloney says. “These results could be practice-changing.”
Unique expertise = better outcomes
Physicians and researchers across SCCA, UW Medicine and Fred Hutch played a key role in developing multiple treatments for lymphoma including CAR T-cell therapies and are constantly devising ways to make these therapies even more effective and less toxic. We’ve also guided more patients through immunotherapy treatment than almost any center in the world. This gives us the expertise to know which therapies are right for a particular patient, to identify complications as early as possible, and to deliver care that gives each patient the best opportunity for a good outcome.
“When a patient is referred to us, we team up with physicians across hematologic malignancies, cell therapy and transplant to identify the best therapy and/or clinical trial,” Dr. Mielcarek says. “That team also includes the referring provider — we partner with them so we can deliver the best possible outcome and return the patient to their care as soon as possible.”